Limits...
QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.

Chen YY, Li Q, Pan CS, Yan L, Fan JY, He K, Sun K, Liu YY, Chen QF, Bai Y, Wang CS, He B, Lv AP, Han JY - Sci Rep (2015)

Bottom Line: QSYQ markedly attenuated CH, as evidenced by echocardiography, morphology and biochemistry.Each ingredient alone or their combinations exhibited similar effects as QSYQ but to a lesser extent and differently with astragaloside IV and notoginsenoside R1 being more effective for enhancing energy metabolism, 3, 4-dihydroxy-phenyl lactic acid more effective for counteracting oxidative stress while dalbergia odorifera having little effect on the variables evaluated.In conclusion, QSYQ exerts a more potent antihypertrophic effect than any of its ingredients or their combinations, due to the interaction of its active components through a multi-component and multi-target mode.

View Article: PubMed Central - PubMed

Affiliation: 1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.

ABSTRACT
The present study aimed to explore the holistic mechanism for the antihypertrophic effect of a compound in Chinese medicine, QiShenYiQi Pills (QSYQ) and the contributions of its components to the effect in rats with cardiac hypertrophy (CH). After induction of CH by ascending aortic stenosis, rats were treated with QSYQ, each identified active ingredient (astragaloside IV, 3, 4-dihydroxy-phenyl lactic acid or notoginsenoside R1) from its 3 major herb components or dalbergia odorifera, either alone or combinations, for 1 month. QSYQ markedly attenuated CH, as evidenced by echocardiography, morphology and biochemistry. Proteomic analysis and western blot showed that the majority of differentially expressed proteins in the heart of QSYQ-treated rats were associated with energy metabolism or oxidative stress. Each ingredient alone or their combinations exhibited similar effects as QSYQ but to a lesser extent and differently with astragaloside IV and notoginsenoside R1 being more effective for enhancing energy metabolism, 3, 4-dihydroxy-phenyl lactic acid more effective for counteracting oxidative stress while dalbergia odorifera having little effect on the variables evaluated. In conclusion, QSYQ exerts a more potent antihypertrophic effect than any of its ingredients or their combinations, due to the interaction of its active components through a multi-component and multi-target mode.

No MeSH data available.


Related in: MedlinePlus

The effect of different drug treatments on enzymes related to energy metabolism tested by western blot and ELISA.a–d The representative western blotting bands and respected semi-quantitative analysis of PFK2 (b), CPT1A (c) and PDH (d), n = 4. e–f Quantitative measurement of ATP/ADP (e) and ATP/AMP (f) by ELISA in each group, n = 6. All bands in figure 6 were cropped from one gel, as shown in Supplementary Fig. S6a with indication of molecular size. The quantification was based on the data of 3 independent experiments and normalized to GAPDH. The data are presented as mean ± S.E. *p < 0.05 vs. Sham, #p < 0.05 vs. AAS1M, †p < 0.05 vs. AAS2M, ‡p < 0.05 vs. QSYQ, $p < 0.05 vs. ASIV, §p < 0.05 vs. DLA, €p < 0.05 vs. R1, Ψp < 0.05 vs. DO.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4488877&req=5

f6: The effect of different drug treatments on enzymes related to energy metabolism tested by western blot and ELISA.a–d The representative western blotting bands and respected semi-quantitative analysis of PFK2 (b), CPT1A (c) and PDH (d), n = 4. e–f Quantitative measurement of ATP/ADP (e) and ATP/AMP (f) by ELISA in each group, n = 6. All bands in figure 6 were cropped from one gel, as shown in Supplementary Fig. S6a with indication of molecular size. The quantification was based on the data of 3 independent experiments and normalized to GAPDH. The data are presented as mean ± S.E. *p < 0.05 vs. Sham, #p < 0.05 vs. AAS1M, †p < 0.05 vs. AAS2M, ‡p < 0.05 vs. QSYQ, $p < 0.05 vs. ASIV, §p < 0.05 vs. DLA, €p < 0.05 vs. R1, Ψp < 0.05 vs. DO.

Mentions: To further gain insight into the mechanism for the effect of different treatments on energy metabolism in CH, we determined the expression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK2), Carnitine palm acyltransferase 1A (CPT1A) and pyruvate dehydrogenase (PDH) in different groups; the results are presented in Fig. 6. As a glycolysis regulator, PFK2 increased significantly in AAS groups, which was protected by QSYQ, ASIV mono- and ASIV containing combination treatments but not others (Fig. 6a,b). In contrast, CPT1A, an enzyme involved in fatty acid oxidation, significantly reduced in AAS groups compared to Sham, which was restored by all the treatments except DLA and R1 mono-therapy or their combination with ASIV (Fig. 6a,c). PDH, a key enzyme of glucose oxidation, significantly decreased in AAS groups as well compared to Sham. All drug treatments but DO restored the expression of PDH as compared to AAS2M group (Fig. 6a,d).


QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode.

Chen YY, Li Q, Pan CS, Yan L, Fan JY, He K, Sun K, Liu YY, Chen QF, Bai Y, Wang CS, He B, Lv AP, Han JY - Sci Rep (2015)

The effect of different drug treatments on enzymes related to energy metabolism tested by western blot and ELISA.a–d The representative western blotting bands and respected semi-quantitative analysis of PFK2 (b), CPT1A (c) and PDH (d), n = 4. e–f Quantitative measurement of ATP/ADP (e) and ATP/AMP (f) by ELISA in each group, n = 6. All bands in figure 6 were cropped from one gel, as shown in Supplementary Fig. S6a with indication of molecular size. The quantification was based on the data of 3 independent experiments and normalized to GAPDH. The data are presented as mean ± S.E. *p < 0.05 vs. Sham, #p < 0.05 vs. AAS1M, †p < 0.05 vs. AAS2M, ‡p < 0.05 vs. QSYQ, $p < 0.05 vs. ASIV, §p < 0.05 vs. DLA, €p < 0.05 vs. R1, Ψp < 0.05 vs. DO.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4488877&req=5

f6: The effect of different drug treatments on enzymes related to energy metabolism tested by western blot and ELISA.a–d The representative western blotting bands and respected semi-quantitative analysis of PFK2 (b), CPT1A (c) and PDH (d), n = 4. e–f Quantitative measurement of ATP/ADP (e) and ATP/AMP (f) by ELISA in each group, n = 6. All bands in figure 6 were cropped from one gel, as shown in Supplementary Fig. S6a with indication of molecular size. The quantification was based on the data of 3 independent experiments and normalized to GAPDH. The data are presented as mean ± S.E. *p < 0.05 vs. Sham, #p < 0.05 vs. AAS1M, †p < 0.05 vs. AAS2M, ‡p < 0.05 vs. QSYQ, $p < 0.05 vs. ASIV, §p < 0.05 vs. DLA, €p < 0.05 vs. R1, Ψp < 0.05 vs. DO.
Mentions: To further gain insight into the mechanism for the effect of different treatments on energy metabolism in CH, we determined the expression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase (PFK2), Carnitine palm acyltransferase 1A (CPT1A) and pyruvate dehydrogenase (PDH) in different groups; the results are presented in Fig. 6. As a glycolysis regulator, PFK2 increased significantly in AAS groups, which was protected by QSYQ, ASIV mono- and ASIV containing combination treatments but not others (Fig. 6a,b). In contrast, CPT1A, an enzyme involved in fatty acid oxidation, significantly reduced in AAS groups compared to Sham, which was restored by all the treatments except DLA and R1 mono-therapy or their combination with ASIV (Fig. 6a,c). PDH, a key enzyme of glucose oxidation, significantly decreased in AAS groups as well compared to Sham. All drug treatments but DO restored the expression of PDH as compared to AAS2M group (Fig. 6a,d).

Bottom Line: QSYQ markedly attenuated CH, as evidenced by echocardiography, morphology and biochemistry.Each ingredient alone or their combinations exhibited similar effects as QSYQ but to a lesser extent and differently with astragaloside IV and notoginsenoside R1 being more effective for enhancing energy metabolism, 3, 4-dihydroxy-phenyl lactic acid more effective for counteracting oxidative stress while dalbergia odorifera having little effect on the variables evaluated.In conclusion, QSYQ exerts a more potent antihypertrophic effect than any of its ingredients or their combinations, due to the interaction of its active components through a multi-component and multi-target mode.

View Article: PubMed Central - PubMed

Affiliation: 1] Department of Integration of Chinese and Western Medicine, School of Basic Medical Sciences, Peking University, Beijing, China [2] Tasly Microcirculation Research Center, Peking University Health Science Center, Beijing, China [3] Key Laboratory of Microcirculation, State Administration of Traditional Chinese Medicine of China, Beijing, China [4] Key Laboratory of Stasis and Phlegm, State Administration of Traditional Chinese Medicine of China, Beijing, China.

ABSTRACT
The present study aimed to explore the holistic mechanism for the antihypertrophic effect of a compound in Chinese medicine, QiShenYiQi Pills (QSYQ) and the contributions of its components to the effect in rats with cardiac hypertrophy (CH). After induction of CH by ascending aortic stenosis, rats were treated with QSYQ, each identified active ingredient (astragaloside IV, 3, 4-dihydroxy-phenyl lactic acid or notoginsenoside R1) from its 3 major herb components or dalbergia odorifera, either alone or combinations, for 1 month. QSYQ markedly attenuated CH, as evidenced by echocardiography, morphology and biochemistry. Proteomic analysis and western blot showed that the majority of differentially expressed proteins in the heart of QSYQ-treated rats were associated with energy metabolism or oxidative stress. Each ingredient alone or their combinations exhibited similar effects as QSYQ but to a lesser extent and differently with astragaloside IV and notoginsenoside R1 being more effective for enhancing energy metabolism, 3, 4-dihydroxy-phenyl lactic acid more effective for counteracting oxidative stress while dalbergia odorifera having little effect on the variables evaluated. In conclusion, QSYQ exerts a more potent antihypertrophic effect than any of its ingredients or their combinations, due to the interaction of its active components through a multi-component and multi-target mode.

No MeSH data available.


Related in: MedlinePlus